Breast cancer (BC) is the most common female malignancy and the second leading cause of cancer-related death worldwide. In spite of significant advances in clinical management, the mortality of BC continues to increase due to the frequent occurrence of treatment resistance. Intensive studies have been conducted to elucidate the molecular mechanisms underlying BC therapeutic resistance, including increased drug efflux, altered drug targets, activated bypass signaling pathways, maintenance of cancer stemness, and deregulated immune response. Emerging evidence suggests that long noncoding RNAs (lncRNAs) are intimately involved in BC therapy resistance through multiple modes of action. Therefore, an in-depth understanding of the implication of lncRNAs in resistance to clinical therapies may improve the clinical outcome of BC patients. Here, we highlight the role and underlying mechanisms of lncRNAs in regulating BC treatment resistance with an emphasis on lncRNAs-mediated resistance in different clinical scenarios, and discuss the potential of lncRNAs as novel biomarkers or therapeutic targets to improve BC therapy response.

中文翻译：

---

管理乳腺癌的治疗耐药性：从 lncRNA 的角度来看。


乳腺癌（BC）是最常见的女性恶性肿瘤，也是全球癌症相关死亡的第二大原因。尽管临床治疗取得了重大进展，但由于治疗耐药的频繁发生，BC 的死亡率仍在持续增加。人们进行了大量研究来阐明乳腺癌治疗耐药性的分子机制，包括增加药物流出、改变药物靶点、激活旁路信号通路、维持癌症干性和失调的免疫反应。新的证据表明，长非编码 RNA (lncRNA) 通过多种作用模式与 BC 治疗耐药密切相关。因此，深入了解lncRNA在临床治疗耐药中的影响可能会改善BC患者的临床结果。在这里，我们强调lncRNA在调节BC治疗耐药中的作用和潜在机制，重点是不同临床情况下lncRNA介导的耐药，并讨论lncRNA作为新型生物标志物或治疗靶点改善BC治疗反应的潜力。